Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 1
2004 2
2005 1
2020 1
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans.
Kjeldsen TB, Hubálek F, Hjørringgaard CU, Tagmose TM, Nishimura E, Stidsen CE, Porsgaard T, Fledelius C, Refsgaard HHF, Gram-Nielsen S, Naver H, Pridal L, Hoeg-Jensen T, Jeppesen CB, Manfè V, Ludvigsen S, Lautrup-Larsen I, Madsen P. Kjeldsen TB, et al. Among authors: tagmose tm. J Med Chem. 2021 Jul 8;64(13):8942-8950. doi: 10.1021/acs.jmedchem.1c00257. Epub 2021 May 4. J Med Chem. 2021. PMID: 33944562 Free article.
Molecular Engineering of Efficacious Mono-Valent Ultra-Long Acting Two-Chain Insulin-Fc Conjugates.
Tagmose TM, Pedersen KM, Pridal L, Stidsen CE, Pedersen MØ, Lin Z, Zhang Y, Wan Z, Ferreras M, Naver H, Nielsen PK, Cao Z, Wang Y, Lykke L, Christensen JL, Jensen VS, Manfè V, Pedersen TÅ, Johansson E, Madsen P, Kodra JT, Münzel M, De Maria L, Nishimura E, Kjeldsen TB. Tagmose TM, et al. J Med Chem. 2022 Feb 10;65(3):2633-2645. doi: 10.1021/acs.jmedchem.1c02039. Epub 2022 Feb 1. J Med Chem. 2022. PMID: 35104142
Engineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320.
Kjeldsen TB, Hubálek F, Tagmose TM, Pridal L, Refsgaard HHF, Porsgaard T, Gram-Nielsen S, Hovgaard L, Valore H, Münzel M, Hjørringgaard CU, Jeppesen CB, Manfè V, Hoeg-Jensen T, Ludvigsen S, Nielsen PK, Lautrup-Larsen I, Stidsen CE, Wulff EM, Garibay PW, Kodra JT, Nishimura E, Madsen P. Kjeldsen TB, et al. Among authors: tagmose tm. J Med Chem. 2021 Jan 14;64(1):616-628. doi: 10.1021/acs.jmedchem.0c01576. Epub 2020 Dec 28. J Med Chem. 2021. PMID: 33356257
NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels.
Huang L, Keyser BM, Tagmose TM, Hansen JB, Taylor JT, Zhuang H, Zhang M, Ragsdale DS, Li M. Huang L, et al. Among authors: tagmose tm. J Pharmacol Exp Ther. 2004 Apr;309(1):193-9. doi: 10.1124/jpet.103.060814. Epub 2004 Jan 12. J Pharmacol Exp Ther. 2004. PMID: 14718587
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
Nielsen FE, Bodvarsdottir TB, Worsaae A, MacKay P, Stidsen CE, Boonen HC, Pridal L, Arkhammar PO, Wahl P, Ynddal L, Junager F, Dragsted N, Tagmose TM, Mogensen JP, Koch A, Treppendahl SP, Hansen JB. Nielsen FE, et al. Among authors: tagmose tm. J Med Chem. 2002 Sep 12;45(19):4171-87. doi: 10.1021/jm0208121. J Med Chem. 2002. PMID: 12213059
Synthesis and pharmacological evaluation of 4H-1,4-benzothiazine-2-carbonitrile 1,1-dioxide and N-(2-cyanomethylsulfonylphenyl)acylamide derivatives as potential activators of ATP sensitive potassium channels.
Schou SC, Hansen HC, Tagmose TM, Boonen HC, Worsaae A, Drabowski M, Wahl P, Arkhammar PO, Bodvarsdottir T, Antoine MH, Lebrun P, Hansen JB. Schou SC, et al. Among authors: tagmose tm. Bioorg Med Chem. 2005 Jan 3;13(1):141-55. doi: 10.1016/j.bmc.2004.09.051. Bioorg Med Chem. 2005. PMID: 15582459